Clinical Trials on Protein Metabolomics

Total 5269 results

Santa Casa de Porto Alegre

Completed

Simvastatin for Treating Erectile Dysfunction (STED)

Erectile Dysfunction | C Reactive Protein | Vascular Disease Detected
Bayer

Completed

BAY14-2222 Continuous Infusion in Surgeries

Hemophilia

Israel
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Hemophilia A

United States
Christian Medical College, Vellore, India

Unknown

Musculoskeletal Function in Hemophilia

Hemophilia

India, Argentina, Brazil, Egypt, Iran, Islamic Republic of, Singapore, South Africa, Thailand, Venezuela
Tourmaline Bio, Inc.

Recruiting

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (TRANQUILITY)

Chronic Kidney Diseases | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | C-Reactive Protein | Chronic Renal Diseases | Kidney Insufficiency, Chronic | hsCRP | High Sensitivity C-Reactive Protein | Hs-CRP

United States
William Shomali
Incyte Corporation

Recruiting

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Eosinophilia | Hypereosinophilic Syndrome | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Splenomegaly | Hepatomegaly | Chronic Eosinophilic Leukemia, Not Otherwise Specified | JAK2 Gene Mutation | BCR-JAK2 Fusion Protein Expression | Blasts 20 Percent or Less of Peripheral Blood White... and other conditions

United States
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Hemophilia A

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Safety and Efficacy Study of NGGT003 in Hemophilia A Patients

Hemophilia A

China
Octapharma

Not yet recruiting

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Hemophilia A

Spain, France, Finland, Germany, Italy, Serbia
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Emotions in the Communication and Relationship Styles of Parents With Hemophilic Children.

Hemophilia A

Italy
GC Biopharma Corp

Recruiting

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

Hemophilia

Korea, Republic of
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Christian Medical College, Vellore, India
Dr. H. Trent Spencer, Professor, Emory University of Medicine, Atlanta Ga...

Recruiting

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Hemophilia A

India
ASC Therapeutics

Recruiting

ASC618 Gene Therapy in Hemophilia A Patients

Hemophilia A

United States
Expression Therapeutics, LLC

Not yet recruiting

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Hemophilia A
University College, London
Medical Research Council

Recruiting

Gene Therapy for Haemophilia A. (GO-8)

Hemophilia A

United States, United Kingdom
Karolinska Institutet

Recruiting

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors

Hemophilia

Sweden
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)

Hemophilia A

Czechia, Switzerland, Denmark, Canada, Australia, Austria, France, United Kingdom, Italy, Sweden, Belgium, Brazil, China, Colombia, Greece, Hungary, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Bayer

Completed

A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

Hemophilia A

China
Baxalta now part of Shire

Active, not recruiting

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Hemophilia A

Spain, Thailand, Hungary, Taiwan, Korea, Republic of, Czechia, Germany, Sweden, Italy, Croatia, United States, Bulgaria, Netherlands
Bioverativ, a Sanofi company

Completed

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (XTEND-Kids)

Hemophilia A

Turkey, Australia, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Pfizer

Active, not recruiting

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Hemophilia A

United States
Genzyme, a Sanofi Company

Active, not recruiting

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Hemophilia

Canada, Italy, Turkey, Spain, United States, India
Swedish Orphan Biovitrum
Cerner Enviza

Completed

Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination (A-MOVE)

Hemophilia A

France
Spark Therapeutics

Active, not recruiting

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Hemophilia A

United States, Canada, Australia
Emory University
Genentech, Inc.

Withdrawn

Emicizumab PUPs and Nuwiq ITI Study

Hemophilia A

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Novikang Medical Technology Co., LTD

Completed

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Hemophilia

China
Takeda
Takeda

Completed

ADYNOVATE Drug Use-Results Survey

Hemophilia A

Japan
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Bayer

Completed

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)

Hemophilia A

Korea, Republic of, Taiwan, Turkey, Singapore, United States, Netherlands, Austria, Denmark, United Kingdom, Belgium, Italy, France, Japan, Germany, Israel, Poland, Canada, Norway, Romania, Colombia
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Sanofi

Completed

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Hemophilia A

Bulgaria
Bayer

Completed

Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)

Hemophilia A

Bulgaria, Spain, Italy, Poland, Greece, Norway, Denmark
Takeda

Completed

A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

Hemophilia A

Canada
Takeda

Completed

A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A (HAPKIDO)

Hemophilia A

Russian Federation
Chulalongkorn University

Completed

Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients

Hemophilia

Thailand
Hospices Civils de Lyon

Completed

Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in France (PASODOBLEDEMI1)

Hemophilia A

France
Bayer
American Thrombosis and Hemostasis Network

Terminated

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Hemophilia A

United States
Swedish Orphan Biovitrum
Bioverativ Therapeutics Inc.

Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (ReITIrate)

Hemophilia A

Ireland, United Kingdom, Germany, United States, Canada, Slovenia, Sweden
Green Cross Corporation
Dream CIS, Inc.

Completed

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Hemophilia

Korea, Republic of
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (STASEY)

Hemophilia A

Canada, Australia, Belgium, India, Germany, Israel, Italy, Spain, Colombia, United Kingdom, Netherlands, Saudi Arabia, Hungary, Guatemala, Russian Federation, Poland, Switzerland, Finland, Panama, Brazil, Mexico, Portugal, Romania, Sw...
Baxalta now part of Shire

Completed

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States
Baxalta now part of Shire

Completed

Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A

Hemophilia A

Germany
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
Baxalta now part of Shire

Completed

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients

Hemophilia A

Czechia, Bulgaria, Hungary, Poland

Clinical Trials on Protein Metabolomics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations